Unlock the potential of adaptive immunity with ImmuneSelect by Virax Biolabs. Investigate T-Cell driven immunity for post-viral syndromes like Long COVID. Explore peptide pools and recombinant antibodies for immune profiling.
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 LONDON, April 25, 2024 /PRNewswire/ .
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vaccine, as monotherapy, 87% had direct ex vivo.